Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.085 AUD | +1.40% | +18.58% | +250.00% |
Apr. 01 | ADRs End Higher; Connect Biopharma Climbs 26% | DJ |
Mar. 28 | ADRs End Lower; NuCana Slides 15% | DJ |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+250.00% | 799M | C | ||
+25.63% | 48.09B | B- | ||
+46.90% | 40.62B | A | ||
-3.15% | 40.43B | B | ||
-6.20% | 28.36B | C | ||
+9.42% | 24.89B | B- | ||
-20.06% | 19.01B | B | ||
+28.93% | 12.09B | C+ | ||
+0.69% | 11.88B | B+ | ||
-1.49% | 11.8B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MSB Stock
- Ratings Mesoblast Limited